Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

High levels of expression of cartilage oligomeric matrix protein in lymph node metastases in breast cancer are associated with reduced survival

Papadakos, Konstantinos S. LU orcid ; Hagerling, Catharina LU ; Rydén, Lisa LU orcid ; Larsson, Anna Maria LU and Blom, Anna M. LU orcid (2021) In Cancers 13(23).
Abstract

Cartilage oligomeric matrix protein (COMP) is a regulator of the extracellular matrix and is expressed primarily in the cartilage. Recently, COMP expression was also documented in breast cancer patients both in sera and tumor biopsies, in both of which it could serve as an independent prognostic marker. This study aimed to assess COMP as a potential biomarker in the group of metastatic breast cancer patients. Levels of COMP were measured by ELISA in serum samples of 141 metastatic breast cancer patients. Biopsies from primary tumors, synchronous lymph node metastases, and distant metastases were stained for COMP expression. The levels of serum COMP were higher in patients with ER‐ and HER2‐positive tumors when compared to... (More)

Cartilage oligomeric matrix protein (COMP) is a regulator of the extracellular matrix and is expressed primarily in the cartilage. Recently, COMP expression was also documented in breast cancer patients both in sera and tumor biopsies, in both of which it could serve as an independent prognostic marker. This study aimed to assess COMP as a potential biomarker in the group of metastatic breast cancer patients. Levels of COMP were measured by ELISA in serum samples of 141 metastatic breast cancer patients. Biopsies from primary tumors, synchronous lymph node metastases, and distant metastases were stained for COMP expression. The levels of serum COMP were higher in patients with ER‐ and HER2‐positive tumors when compared to triple‐negative tumors and correlated with the presence of bone and lung metastases, circulating tumor cell count, and clusters. Most of the primary tumors expressing COMP (70%) retained the expression also in the lymph node metastases, which correlated with visceral metastases and reduced survival. In conclusion, COMP appears as a valuable biomarker in metastatic breast cancer patients indicating a more severe stage of the disease. Serum COMP levels were associated with specific types of metastases in patients with metastatic breast cancer emphasizing that further studies are warranted to elucidate its potential role as a monitoring marker.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
COMP, Lymph node metastases, Metastatic patients, Serum‐COMP
in
Cancers
volume
13
issue
23
article number
5876
publisher
MDPI AG
external identifiers
  • scopus:85119607798
  • pmid:34884987
ISSN
2072-6694
DOI
10.3390/cancers13235876
language
English
LU publication?
yes
id
a27a8aca-5b8e-45b0-b4b8-d1a0d3b73525
date added to LUP
2021-12-08 13:40:09
date last changed
2024-06-15 22:16:38
@article{a27a8aca-5b8e-45b0-b4b8-d1a0d3b73525,
  abstract     = {{<p>Cartilage oligomeric matrix protein (COMP) is a regulator of the extracellular matrix and is expressed primarily in the cartilage. Recently, COMP expression was also documented in breast cancer patients both in sera and tumor biopsies, in both of which it could serve as an independent prognostic marker. This study aimed to assess COMP as a potential biomarker in the group of metastatic breast cancer patients. Levels of COMP were measured by ELISA in serum samples of 141 metastatic breast cancer patients. Biopsies from primary tumors, synchronous lymph node metastases, and distant metastases were stained for COMP expression. The levels of serum COMP were higher in patients with ER‐ and HER2‐positive tumors when compared to triple‐negative tumors and correlated with the presence of bone and lung metastases, circulating tumor cell count, and clusters. Most of the primary tumors expressing COMP (70%) retained the expression also in the lymph node metastases, which correlated with visceral metastases and reduced survival. In conclusion, COMP appears as a valuable biomarker in metastatic breast cancer patients indicating a more severe stage of the disease. Serum COMP levels were associated with specific types of metastases in patients with metastatic breast cancer emphasizing that further studies are warranted to elucidate its potential role as a monitoring marker.</p>}},
  author       = {{Papadakos, Konstantinos S. and Hagerling, Catharina and Rydén, Lisa and Larsson, Anna Maria and Blom, Anna M.}},
  issn         = {{2072-6694}},
  keywords     = {{COMP; Lymph node metastases; Metastatic patients; Serum‐COMP}},
  language     = {{eng}},
  number       = {{23}},
  publisher    = {{MDPI AG}},
  series       = {{Cancers}},
  title        = {{High levels of expression of cartilage oligomeric matrix protein in lymph node metastases in breast cancer are associated with reduced survival}},
  url          = {{http://dx.doi.org/10.3390/cancers13235876}},
  doi          = {{10.3390/cancers13235876}},
  volume       = {{13}},
  year         = {{2021}},
}